Ciorcan Mircea, Negru Șerban, Bardan Răzvan, Cumpănaș Alin, Mattar Iasmina, Bitar Yahya, Chișavu Lazăr, Marc Luciana, Schiller Adalbert, Mihăescu Adelina
Department of Clinical Practical Skills, Victor Babes University of Medicine and Pharmacy, 300041 Timișoara, Romania.
Center of Advanced Research in Cardiovascular Pathology and Hemostaseology, Victor Babes University of Medicine and Pharmacy, 300041 Timișoara, Romania.
J Pers Med. 2023 Nov 3;13(11):1572. doi: 10.3390/jpm13111572.
(1) Background: The relationship between chronic kidney disease (CKD) and urological cancers is complex, as most of these cancers are diagnosed in patients with advanced ages, when the kidney function may be already impaired. On the other hand, urological cancers could represent a risk factor for CKD, significantly reducing the life expectancy of the patients. The main objective of our study was to analyze the impact of CKD on the overall mortality of patients diagnosed with the most frequent types of urological cancers. (2) Material and Methods: We conducted an observational retrospective cohort study on a group of 5831 consecutive newly diagnosed cancer patients, followed over a 2-year period (2019-2020), from a large Oncology Hospital in Romania. From this group, we selected only the patients diagnosed with urological malignancies, focusing on prostate cancer, bladder cancer and renal cancer; finally, 249 patients were included in our analysis. (3) Results: In the group of patients with prostate cancer ( = 146), the 2-year overall mortality was 62.5% for patients with CKD, compared with 39.3% for those with no initial CKD ( < 0.05). In the group of patients with bladder cancer ( = 62), the 2-year overall mortality was 80% for patients with initial CKD, compared with 45.2% for the patients with no initial CKD ( < 0.05). Finally, in the group of patients with renal cell carcinoma ( = 41), the 2-year overall mortality was 60% for patients with initial CKD, compared with 50% for the patient group with no initial CKD ( < 0.05). Various correlations between specific oncologic and nephrological parameters were also analyzed. (4) Conclusions: The presence of CKD at the moment of the urological cancer diagnosis is associated with significantly higher 2-year mortality rates.
(1) 背景:慢性肾脏病(CKD)与泌尿系统癌症之间的关系较为复杂,因为这些癌症大多在老年患者中被诊断出来,而此时肾功能可能已经受损。另一方面,泌尿系统癌症可能是CKD的一个危险因素,会显著降低患者的预期寿命。我们研究的主要目的是分析CKD对被诊断为最常见类型泌尿系统癌症患者的总体死亡率的影响。(2) 材料与方法:我们对罗马尼亚一家大型肿瘤医院的5831例连续新诊断癌症患者进行了一项观察性回顾性队列研究,随访时间为2年(2019 - 2020年)。从该组患者中,我们仅选择被诊断为泌尿系统恶性肿瘤的患者,重点关注前列腺癌([此处英文“前列腺癌”单词缺失])、膀胱癌和肾癌;最终,249例患者纳入我们的分析。(3) 结果:在前列腺癌患者组([此处英文“前列腺癌”单词缺失]=146)中,初始患有CKD的患者2年总体死亡率为62.5%,而初始无CKD的患者为39.3%([此处英文“<”单词缺失]0.05)。在膀胱癌患者组([此处英文“膀胱癌”单词缺失]=62)中,初始患有CKD的患者2年总体死亡率为80%,而初始无CKD的患者为45.2%([此处英文“<”单词缺失]0.05)。最后,在肾细胞癌患者组([此处英文“肾细胞癌”单词缺失]=41)中,初始患有CKD的患者2年总体死亡率为60%,而初始无CKD的患者组为50%([此处英文“<”单词缺失]0.05)。还分析了特定肿瘤学和肾脏病学参数之间的各种相关性。(4) 结论:泌尿系统癌症诊断时存在CKD与显著更高的2年死亡率相关。